Clinical trial
A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00068081 is registered in ClinicalTrials.gov with NeurogesX as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
- Lead sponsor
- NeurogesX
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 150
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.